European review for medical and pharmacological sciences最新文献

{"title":"Retraction Note: Oxycodone inhibits myocardial cell apoptosis after myocardial ischemia-reperfusion injury in rats via RhoA/ROCK1 signaling pathway.","authors":"Y Xie, C-L Ge, Z-Y Zhang, G-X Fei","doi":"10.26355/eurrev_202606_37851","DOIUrl":"https://doi.org/10.26355/eurrev_202606_37851","url":null,"abstract":"<p><p>The article \"Oxycodone inhibits myocardial cell apoptosis after myocardial ischemia-reperfusion injury in rats via RhoA/ROCK1 signaling pathway\" by Y. Xie, C.-L. Ge, Z.-Y. Zhang, G.-X. Fei, published in Eur Rev Med Pharmacol Sci 2020; 24 (11): 6371-6379-DOI: 10.26355/eurrev_202006_21535-PMID: 32572934, has been retracted by the Publisher and the Editor in Chief. Following publication, concerns were raised by a third party regarding the integrity of several figures. An editorial assessment revealed multiple instances of image duplication within the article and image duplication with previously published articles by different authors. The authors have been contacted and were asked to provide the original data; however, they did not respond to the journal's correspondence. As a result, the Editor-in-Chief has lost confidence in the reliability of the data presented in this article and has decided to retract it.  This article has been retracted. The Publisher apologizes for any inconvenience this may cause.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 6","pages":"192"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148374855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From models to medicine: advanced preclinical systems and AI enabling RNA therapeutics in triple-negative breast cancer.","authors":"C Esposito, I Bello, E Panza","doi":"10.26355/eurrev_202606_37857","DOIUrl":"https://doi.org/10.26355/eurrev_202606_37857","url":null,"abstract":"<p><p>Triple-negative breast cancer (TNBC) is one of the most aggressive breast cancer subtypes, characterized by the lack of actionable molecular targets, pronounced intratumoral heterogeneity, and a highly dynamic tumor microenvironment (TME). RNA-based therapeutics, including messenger RNA (mRNA), small interfering RNA (siRNA), antisense oligonucleotides, and non-coding RNAs, represent a promising strategy for modulating gene expression and targeting previously undruggable pathways. Nevertheless, their clinical application in TNBC remains limited. This review aims to critically evaluate the main biological and technological barriers to RNA therapeutics in TNBC and to highlight emerging strategies to enhance their translational potential, with particular emphasis on advanced preclinical models and artificial intelligence (AI). The limited clinical success of RNA therapeutics in TNBC is primarily due to intrinsic RNA instability, rapid nuclease-mediated degradation, suboptimal and heterogeneous tumor delivery, and sequence-dependent off-target effects. Traditional two-dimensional in vitro models inadequately reproduce tumor architecture and TME complexity, resulting in poor predictive value. In contrast, advanced preclinical platforms-including three-dimensional spheroids, patient-derived organoids, organ-on-chip systems, and patient-derived xenografts-better recapitulate tumor biology, cell-microenvironment interactions, and interpatient variability. Concurrently, AI and machine learning approaches are increasingly employed to optimize RNA sequence design, predict off-target effects, improve nanoparticle-based delivery systems, integrate multi-omics and spatial transcriptomics data, and support patient stratification. The integration of physiologically relevant preclinical models with AI-driven approaches represents a promising strategy to overcome current limitations in RNA-based therapeutics for TNBC. This multidisciplinary framework may enhance delivery efficiency, reduce attrition rates, and accelerate the development of RNA-based precision oncology strategies in TNBC.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 6","pages":"214-228"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients.","authors":"I Hernandez Marin, O Picconi, A S Laganà, L Costabile, V Unfer","doi":"10.26355/eurrev_202606_37853","DOIUrl":"https://doi.org/10.26355/eurrev_202606_37853","url":null,"abstract":"<p><p>The article \"A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients\" by I. Hernandez Marin, O. Picconi, A.S. Laganà, L. Costabile, V. Unfer, published in Eur Rev Med Pharmacol Sci 2021; 25 (8): 3316-3324-DOI: 10.26355/eurrev_202104_25743-PMID: 33928619, has been retracted by the Publisher and the Editor in Chief. Following concerns raised by a whistleblower regarding ethics approval issues, statistical analysis, the reliability of the reported results, and potential conflicts of interest, the journal initiated an editorial investigation in accordance with journal policies and COPE guidelines. The authors were contacted and provided a response as well as the original data. An independent statistical expert was appointed to reassess the manuscript. The evaluation identified insufficient documentation of ethics approval across all participating centers and unresolved methodological and statistical concerns, which together limit the reliability and interpretability of the reported findings. In light of these issues, the Editor-in-Chief has concluded that the article's results and conclusions are compromised. The article is therefore retracted. The authors have been informed of this decision and do not agree with the retraction. This article has been retracted. The Publisher apologizes for any inconvenience this may cause.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 6","pages":"193"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148374913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of serum asprosin levels with obesity indices and metabolic parameters in adults.","authors":"S Çetin, I Solmaz, J Kılıç, Ö F Alakuş, Ö Aslan, M A Coşkuner, B B Başgöz","doi":"10.26355/eurrev_202606_37856","DOIUrl":"https://doi.org/10.26355/eurrev_202606_37856","url":null,"abstract":"<p><strong>Objective: </strong>Asprosin is a recently identified adipokine secreted predominantly by white adipose tissue and is implicated in energy homeostasis, insulin resistance, and inflammatory pathways. Emerging evidence suggests a close association between asprosin and obesity-related metabolic disturbances. This study aimed to investigate the relationship between serum asprosin levels and obesity- and metabolism-related parameters, including body mass index (BMI), visceral adiposity index (VAI), anthropometric measurements, and biochemical markers.  MATERIALS AND METHODS: This retrospective cross-sectional study was conducted using data from patients who attended the Internal Medicine and Obesity Outpatient Clinics of Gazi Yaşargil Training and Research Hospital between January 2022 and December 2023. Participants were categorized into normal-weight (n = 55), overweight (n = 40), and obese (n = 60) groups according to BMI. Laboratory parameters, including serum asprosin levels, lipid profile, HbA1c, and VAI, were analyzed using previously collected fasting serum samples.  RESULTS: Serum asprosin levels differed significantly among BMI groups and were higher in overweight and obese individuals compared to normal-weight participants (p < 0.001). Asprosin levels showed significant positive correlations with BMI, VAI, triglyceride levels, and platelet count, and a significant negative correlation with high-density lipoprotein (HDL) cholesterol. No significant associations were found between asprosin levels and HbA1c, low-density lipoprotein (LDL) cholesterol, aspartate aminotransferase (AST), or alanine aminotransferase (ALT).</p><p><strong>Conclusions: </strong>Serum asprosin is closely associated with adiposity and lipid-related metabolic alterations, suggesting its potential role as a biomarker in obesity-related metabolic disorders. However, further longitudinal studies are required to clarify its clinical utility.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 6","pages":"202-213"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Can the endometrioma be an obstacle to complete oocyte retrieval in IVF cycles? A retrospective study.","authors":"G M Baldini, A S Laganà, A Mastrorocco, A Malvasi, D Baldini, D Ferri, R Sciorio, G Trojano","doi":"10.26355/eurrev_202606_37854","DOIUrl":"10.26355/eurrev_202606_37854","url":null,"abstract":"<p><p>The article \"Can the endometrioma be an obstacle to complete oocyte retrieval in IVF cycles? A retrospective study\" by G.M. Baldini, A.S. Laganà, A. Mastrorocco, A. Malvasi, D. Baldini, D. Ferri, R. Sciorio, G. Trojano, published in Eur Rev Med Pharmacol Sci 2024; 28 (7): 2827-2836-DOI: 10.26355/eurrev_202404_35911-PMID: 38639522, has been retracted by the Publisher and the Editor in Chief. Following concerns raised on the study data and ethics issues, the journal initiated an editorial investigation in accordance with journal policies and COPE guidelines. The authors were contacted and provided a reply to the issues raised, but were unable to provide the original data due to a technical failure that resulted in the loss of access to the underlying files, nor the original ethics committee approval document. The journal has therefore reassessed the manuscript based on the information provided. The external evaluation identified significant concerns regarding the study's reporting, transparency, and verifiability. Consequently, the concerns raised during the post-publication evaluation could not be satisfactorily resolved, and the reliability of the reported findings and conclusions could not be verified. In light of these issues, the Editor-in-Chief has concluded that the article is retracted. The authors have been informed of this decision and do not agree with the retraction. This article has been retracted. The Publisher apologizes for any inconvenience this may cause.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 6","pages":"194"},"PeriodicalIF":3.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148374892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics, management strategies, and outcomes of pediatric immune thrombocytopenic purpura: a five-year single-center experience.","authors":"Ö S Kaya, E G Kazancı, D Güven, B Orhaner","doi":"10.26355/eurrev_202605_37820","DOIUrl":"10.26355/eurrev_202605_37820","url":null,"abstract":"<p><strong>Objective: </strong>Immune thrombocytopenia (ITP), which is caused by immune-mediated platelet loss, is the most common cause of acquired thrombocytopenia in pediatric patients. In addition to evaluating treatment approaches and outcomes within a single-center cohort, this study aimed to evaluate the clinical and laboratory characteristics of juvenile ITP.</p><p><strong>Materials and methods: </strong>Out of 296 patients with thrombocytopenia, 135 children (ages 0-18) with acute ITP were included in this retrospective analysis. We reviewed clinical observations, laboratory results, therapeutic modalities, length of hospital stay, demographic data, and treatment outcomes.</p><p><strong>Results: </strong>Out of 296 patients, 161 (54.4%) had secondary thrombocytopenia, and 135 (45.6%) had ITP. 51.1% of the population was female, and the average age was 5.5±3.97 years. The most common symptoms were petechiae (40%) and ecchymosis (46.7%). 83.7% of patients received intravenous immunoglobulin (IVIG), resulting in a 91.2% response rate after a single dose. 14.1% of patients received corticosteroids, and most of them achieved platelet counts ≥30,000/mm³. In 15.6% of cases, bone marrow aspiration was performed prior to the start of steroid treatment. Splenectomy was required in 0.7% of cases, and rituximab in 1.5%. There was no discernible variation in the treatment response between the modalities (p=0.34). Secondary thrombocytopenia (n=161) was primarily caused by infection (64.5%), with Epstein-Barr virus being found in 3.7% of cases.</p><p><strong>Conclusions: </strong>IVIG promoted rapid platelet recovery with high responder rates. Overall, the results were favorable, and there were no discernible differences between the treatment plans.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 5","pages":"154-163"},"PeriodicalIF":3.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the acceptability of effervescent oxycodone/paracetamol in the management of moderate-to-severe pain: the FirAlgos study.","authors":"R Vellucci, E Tur, A Lepri, S Gasperoni, L Dodaro, C Simoni, Z Momirovic, S Romagnoli","doi":"10.26355/eurrev_202605_37822","DOIUrl":"10.26355/eurrev_202605_37822","url":null,"abstract":"<p><strong>Objective: </strong>Chronic pain affects approximately one quarter of the Italian adult population and represents a major public health burden, significantly impairing quality of life and functional capacity. When first-line analgesics are insufficient, opioid combinations such as oxycodone/paracetamol (OXY/PAR) are recommended. The effervescent formulation of OXY/PAR was developed to improve administration and acceptability, particularly in frail patients or those with swallowing difficulties. The FirAlgos study evaluated its real-world effectiveness and patient-reported acceptability.</p><p><strong>Materials and methods: </strong>This retrospective observational study included adult patients treated with effervescent OXY/PAR for moderate-to-severe pain (NRS >5) at a tertiary Pain Therapy Center (2022-2023). Assessments were performed at baseline (T0), Day 7 (T1), and Day 14 (T2). Outcomes included pain intensity (Numeric Rating Scale, NRS), pain interference (Brief Pain Inventory, BPI), Patient Global Impression of Change (PGIC), and treatment satisfaction. Longitudinal changes were analyzed using Friedman's Chi-Square test with Wilcoxon post-hoc correction.</p><p><strong>Results: </strong>Ninety-four patients were included (mean age 69.3 ± 13.3 years; 59.6% female; 75.5% non-oncologic pain). Significant reductions in NRS scores were observed between T0 and T1 across all pain dimensions in both oncologic and non-oncologic groups (p < 0.05), with stabilization at T2. PGIC scores showed a rapid upward shift toward higher perceived improvement categories, maintained at follow-up. BPI analyses demonstrated significant early improvements in functional domains, particularly general activity, mobility, and work capability, with sustained benefit over time.</p><p><strong>Conclusions: </strong>In real-world clinical practice, the effervescent OXY/PAR formulation provided rapid, clinically meaningful, and sustained pain relief, with parallel improvements in functional outcomes and patient-perceived benefit. Its high acceptability supports its use in patients requiring flexible and easily administrable analgesic options for moderate-to-severe pain.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 5","pages":"181-191"},"PeriodicalIF":3.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a new diagnostic tool for detecting cervical cancer using a TCR-like antibody targeting the HPV 16 oncoprotein E7.","authors":"R Selva Rajan, S A Dass, B A Sachit, G J Tye, V Balakrishnan","doi":"10.26355/eurrev_202605_37821","DOIUrl":"10.26355/eurrev_202605_37821","url":null,"abstract":"<p><strong>Objective: </strong>Persistent Human Papillomavirus (HPV) infection causes 84% of cervical cancers (CC) worldwide. The current gold standard, Pap smear, has a high false-negative rate, highlighting the need for a specific and sensitive molecular method for early diagnosis. T cell receptor (TCR)-like antibodies offer a promising platform for cancer immunodiagnostics and immunotherapy.</p><p><strong>Materials and methods: </strong>Using the phage display technique, a monoclonal TCR-like antibody (16 Ab) against HPV 16 oncoprotein E7 for human leukocyte antigen (HLA)-A2 was produced in this study. 16 Ab was selected from a single-domain antibody (sDAb) library via biopanning, an affinity-selection method. Once the clone of 16 Ab was selected, it was sequenced, and the result was analyzed using IMGT/V-Quest and VBase2 databases before proceeding with 16 Ab protein expression and purification. The purified 16 Ab was evaluated for its binding capability towards its target peptide-major histocompatibility complex (pMHC) by Western blot and Enzyme-Linked immunosorbent assay (ELISA).</p><p><strong>Results: </strong>A target pMHC complex was generated and panned against a phage display library. Highly enriched antibody phages from the 3rd biopanning round were chosen for phage ELISA analyses. Of the nine clones selected and sequenced, only two had proper sequences, and 16 Ab was chosen for the downstream process because it shows higher specificity for the target pMHC complex than the other clones. The dot blot showed that the soluble protein from 16 Ab was successfully expressed. The binding of 16 Ab towards the target pMHC complex (OD405 nm: 1.06) significantly differs from the non-target pMHC complex (OD405 nm: 0.09).</p><p><strong>Conclusions: </strong>This study demonstrates the potential of 16 Ab as a companion diagnostic to reduce the rate of false-negative Pap smears. Further research is needed to assess its therapeutic potential, expand coverage to all HPV variants and HLA types, and evaluate its performance in cervical cancer cell lines before clinical testing.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 5","pages":"164-180"},"PeriodicalIF":3.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: \"Putative underlying mechanisms of lipid emulsion treatment for aluminum phosphide poisoning&#8221.","authors":"M Singh Bhatia, R Attri, A Saroch, A Kumar Pannu, N Singla, S Chandrabhan Sharda","doi":"10.26355/eurrev_202604_37750","DOIUrl":"https://doi.org/10.26355/eurrev_202604_37750","url":null,"abstract":"","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 4","pages":"131-132"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Antisepsis regimen in the surgical treatment of HPV generated cervical lesions: polyhexamethylene biguanide vs chlorhexidine. A randomized, double blind study.","authors":"S Gerli, F Bavetta, G C Di Renzo","doi":"10.26355/eurrev_202604_37746","DOIUrl":"https://doi.org/10.26355/eurrev_202604_37746","url":null,"abstract":"<p><p>The article \"Antisepsis regimen in the surgical treatment of HPV generated cervical lesions: polyhexamethylene biguanide vs chlorhexidine. A randomized, double blind study\" by S. Gerli, F. Bavetta, G.C. Di Renzo, published in European Review for Medical and Pharmacological Sciences 2012; 16: 1994-1998-PMID: 23242728, has been retracted by the Publisher and the Editor in Chief. Following concerns raised by a whistleblower regarding the statistical analysis and the reliability of the reported results, the journal initiated an editorial investigation in accordance with ethical policies. The authors were contacted and provided a response. An independent statistical expert was also appointed to reassess the methodology and data analysis. The evaluation identified significant methodological and statistical concerns that affect the validity and interpretation of the study findings. In light of these issues, the Editor-in-Chief has concluded that the reliability of the results and the conclusions of the article are compromised. The article is therefore retracted. This article has been retracted. The Publisher apologizes for any inconvenience this may cause.</p>","PeriodicalId":12152,"journal":{"name":"European review for medical and pharmacological sciences","volume":"30 4","pages":"126"},"PeriodicalIF":3.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}